DSM-Firmenich stock faces November 4 sales update
Published on 11/01/2026 at 17:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSWhat investors should watch next
- DSM-Firmenich is due to release its third-quarter trading update on Wednesday, November 4.
- First-half like-for-like sales growth reached 5%, while management retained its full-year growth outlook.
- The update will test progress toward a consumer-focused portfolio after the planned Animal Nutrition & Health separation.
DSM-Firmenich will publish its third-quarter 2026 trading update on Wednesday, November 4, putting sales momentum and the group's portfolio reshaping in focus for investors. The appointment is highlighted by Kurums in its October 20 company review, which also points to first-half like-for-like sales growth of 5%.
Sales update takes center stage
The November 4 release is the next scheduled corporate milestone after the group reported first-half sales from continuing operations of EUR 4,664 million, according to the Kurums review. Adjusted EBITDA reached EUR 900 million, while the margin was 19.3%, slightly below the prior-year level cited in the same report.
Management has retained its 2026 outlook for like-for-like growth of 2% to 4%, with performance expected toward the upper end of that range. It also targets an Adjusted EBITDA margin of around 20% and adjusted gross operating free cash flow of 11% to 12% of sales.
Portfolio reshaping remains central
The trading update will arrive as DSM-Firmenich continues its exit from Animal Nutrition & Health. The group agreed to sell the remaining business to CVC Capital Partners at an enterprise value of about EUR 2.2 billion, while retaining a 20% stake in the two planned standalone companies. Closing is expected around the end of 2026, subject to regulatory approvals and employee consultations.
The strategy leaves Perfumery & Beauty, Taste, Texture & Health, and Health, Nutrition & Care as the continuing businesses. Kurums reported continuing-operations sales of EUR 9,034 million for 2025 and an Adjusted EBITDA margin of 19.6%, giving investors a reference point for the group's consumer-ingredients focus.
The real-time quote of DSM-Firmenich stock was 106.75 euros on Lang & Schwarz at 17:06 CET on Sunday, November 1, 2026.
DSM-Firmenich investor facts
- Company: DSM-Firmenich AG
- ISIN: CH1216478797
- Lang & Schwarz quote: EUR 106.75 on November 1, 2026, at 17:06 CET
- 52-week range: EUR 55.22 to EUR 109.85
- Market capitalization: EUR 26,085,563,438
- Primary listing: Euronext Amsterdam
Broader market context is available in the latest European market reports.
Investors can follow the company's next sales signal and subsequent portfolio milestones through more news and analyses on DSM-Firmenich stock.
